Annual Current Liabilities
$3.94 B
+$520.90 M+15.22%
December 31, 2024
Summary
- As of February 22, 2025, REGN annual total current liabilities is $3.94 billion, with the most recent change of +$520.90 million (+15.22%) on December 31, 2024.
- During the last 3 years, REGN annual current liabilities has risen by +$11.80 million (+0.30%).
- REGN annual current liabilities is now at all-time high.
Performance
REGN Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$3.94 B
+$283.30 M+7.74%
December 31, 2024
Summary
- As of February 22, 2025, REGN quarterly total current liabilities is $3.94 billion, with the most recent change of +$283.30 million (+7.74%) on December 31, 2024.
- Over the past year, REGN quarterly current liabilities has increased by +$520.90 million (+15.22%).
- REGN quarterly current liabilities is now at all-time high.
Performance
REGN Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
REGN Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +15.2% | +15.2% |
| 3 y3 years | +0.3% | +15.2% |
| 5 y5 years | +88.1% | +15.2% |
REGN Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +25.6% | at high | +37.0% |
| 5 y | 5-year | at high | +88.1% | at high | +91.9% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Regeneron Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $3.94 B(+15.2%) | $3.94 B(+7.7%) |
| Sep 2024 | - | $3.66 B(+4.3%) |
| Jun 2024 | - | $3.51 B(-2.0%) |
| Mar 2024 | - | $3.58 B(+4.6%) |
| Dec 2023 | $3.42 B(+9.0%) | $3.42 B(-4.9%) |
| Sep 2023 | - | $3.60 B(+15.9%) |
| Jun 2023 | - | $3.10 B(+0.1%) |
| Mar 2023 | - | $3.10 B(-1.3%) |
| Dec 2022 | $3.14 B(-20.1%) | $3.14 B(+9.1%) |
| Sep 2022 | - | $2.88 B(-5.1%) |
| Jun 2022 | - | $3.03 B(+0.9%) |
| Mar 2022 | - | $3.01 B(-23.5%) |
| Dec 2021 | $3.93 B(+45.8%) | $3.93 B(+5.9%) |
| Sep 2021 | - | $3.71 B(-0.5%) |
| Jun 2021 | - | $3.73 B(+16.0%) |
| Mar 2021 | - | $3.22 B(+19.3%) |
| Dec 2020 | $2.70 B(+28.7%) | $2.70 B(+15.4%) |
| Sep 2020 | - | $2.34 B(-36.9%) |
| Jun 2020 | - | $3.70 B(+80.1%) |
| Mar 2020 | - | $2.06 B(-2.0%) |
| Dec 2019 | $2.10 B(+45.3%) | $2.10 B(+18.8%) |
| Sep 2019 | - | $1.77 B(+3.1%) |
| Jun 2019 | - | $1.71 B(+13.3%) |
| Mar 2019 | - | $1.51 B(+4.8%) |
| Dec 2018 | $1.44 B(+27.1%) | $1.44 B(+1.8%) |
| Sep 2018 | - | $1.42 B(+6.5%) |
| Jun 2018 | - | $1.33 B(+5.2%) |
| Mar 2018 | - | $1.27 B(+11.5%) |
| Dec 2017 | $1.14 B(-8.5%) | $1.14 B(-0.3%) |
| Sep 2017 | - | $1.14 B(+10.7%) |
| Jun 2017 | - | $1.03 B(-21.3%) |
| Mar 2017 | - | $1.31 B(+5.4%) |
| Dec 2016 | $1.24 B(+53.1%) | $1.24 B(+29.2%) |
| Sep 2016 | - | $961.18 M(+1.0%) |
| Jun 2016 | - | $951.56 M(+3.5%) |
| Mar 2016 | - | $919.72 M(+13.4%) |
| Dec 2015 | $811.16 M(+23.9%) | $811.16 M(+10.4%) |
| Sep 2015 | - | $734.99 M(+22.2%) |
| Jun 2015 | - | $601.54 M(+12.2%) |
| Mar 2015 | - | $536.13 M(-18.1%) |
| Dec 2014 | $654.66 M(+119.1%) | $654.66 M(+59.6%) |
| Sep 2014 | - | $410.20 M(+16.7%) |
| Jun 2014 | - | $351.58 M(+15.2%) |
| Mar 2014 | - | $305.07 M(+2.1%) |
| Dec 2013 | $298.83 M(+82.7%) | $298.83 M(+11.2%) |
| Sep 2013 | - | $268.73 M(+31.9%) |
| Jun 2013 | - | $203.80 M(+3.3%) |
| Mar 2013 | - | $197.24 M(+20.6%) |
| Dec 2012 | $163.55 M(+10.3%) | $163.55 M(-8.4%) |
| Sep 2012 | - | $178.57 M(-2.5%) |
| Jun 2012 | - | $183.22 M(+14.2%) |
| Mar 2012 | - | $160.39 M(+8.2%) |
| Dec 2011 | $148.27 M(+36.0%) | $148.27 M(+11.3%) |
| Sep 2011 | - | $133.24 M(-1.9%) |
| Jun 2011 | - | $135.87 M(+21.0%) |
| Mar 2011 | - | $112.25 M(+2.9%) |
| Dec 2010 | $109.06 M(+16.5%) | $109.06 M(-18.5%) |
| Sep 2010 | - | $133.83 M(+11.9%) |
| Jun 2010 | - | $119.57 M(+14.9%) |
| Mar 2010 | - | $104.09 M(+11.2%) |
| Dec 2009 | $93.58 M(+11.8%) | $93.58 M(-18.0%) |
| Sep 2009 | - | $114.17 M(-5.2%) |
| Jun 2009 | - | $120.42 M(+16.8%) |
| Mar 2009 | - | $103.11 M(+23.2%) |
| Dec 2008 | $83.67 M(-70.5%) | $83.67 M(-61.6%) |
| Sep 2008 | - | $217.77 M(-2.7%) |
| Jun 2008 | - | $223.92 M(-21.7%) |
| Mar 2008 | - | $285.95 M(+0.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $283.66 M(+530.2%) | $283.66 M(+193.4%) |
| Sep 2007 | - | $96.69 M(-7.8%) |
| Jun 2007 | - | $104.83 M(+25.4%) |
| Mar 2007 | - | $83.60 M(+85.7%) |
| Dec 2006 | $45.01 M(+11.5%) | $45.01 M(+37.7%) |
| Sep 2006 | - | $32.70 M(+3.8%) |
| Jun 2006 | - | $31.51 M(-6.4%) |
| Mar 2006 | - | $33.67 M(-16.6%) |
| Dec 2005 | $40.36 M(+18.2%) | $40.36 M(+20.4%) |
| Sep 2005 | - | $33.52 M(+11.9%) |
| Jun 2005 | - | $29.95 M(+0.1%) |
| Mar 2005 | - | $29.93 M(-12.3%) |
| Dec 2004 | $34.14 M(-53.2%) | $34.14 M(-4.9%) |
| Sep 2004 | - | $35.90 M(-3.9%) |
| Jun 2004 | - | $37.37 M(+2.9%) |
| Mar 2004 | - | $36.34 M(-50.2%) |
| Dec 2003 | $72.92 M(+81.8%) | $72.92 M(+33.2%) |
| Sep 2003 | - | $54.74 M(+11.6%) |
| Jun 2003 | - | $49.06 M(-17.4%) |
| Mar 2003 | - | $59.37 M(+48.0%) |
| Dec 2002 | $40.12 M(+82.2%) | $40.12 M(+22.9%) |
| Sep 2002 | - | $32.65 M(+52.0%) |
| Jun 2002 | - | $21.48 M(-6.4%) |
| Mar 2002 | - | $22.94 M(+4.2%) |
| Dec 2001 | $22.02 M(+59.7%) | $22.02 M(+52.8%) |
| Sep 2001 | - | $14.41 M(+11.5%) |
| Jun 2001 | - | $12.93 M(-6.7%) |
| Mar 2001 | - | $13.86 M(+0.5%) |
| Dec 2000 | $13.79 M(+3.7%) | $13.79 M(+8.2%) |
| Sep 2000 | - | $12.74 M(-2.2%) |
| Jun 2000 | - | $13.03 M(+4.6%) |
| Mar 2000 | - | $12.45 M(-6.4%) |
| Dec 1999 | $13.30 M(+41.5%) | $13.30 M(+49.4%) |
| Sep 1999 | - | $8.90 M(+2.3%) |
| Jun 1999 | - | $8.70 M(-12.1%) |
| Mar 1999 | - | $9.90 M(+5.3%) |
| Dec 1998 | $9.40 M(-12.1%) | $9.40 M(-2.1%) |
| Sep 1998 | - | $9.60 M(+12.9%) |
| Jun 1998 | - | $8.50 M(+13.3%) |
| Mar 1998 | - | $7.50 M(-29.9%) |
| Dec 1997 | $10.70 M(-10.8%) | $10.70 M(+37.2%) |
| Sep 1997 | - | $7.80 M(-27.8%) |
| Jun 1997 | - | $10.80 M(+11.3%) |
| Mar 1997 | - | $9.70 M(-19.2%) |
| Dec 1996 | $12.00 M(-7.0%) | $12.00 M(+34.8%) |
| Sep 1996 | - | $8.90 M(-7.3%) |
| Jun 1996 | - | $9.60 M(-8.6%) |
| Mar 1996 | - | $10.50 M(-18.6%) |
| Dec 1995 | $12.90 M(-27.9%) | $12.90 M(-8.5%) |
| Sep 1995 | - | $14.10 M(-13.0%) |
| Jun 1995 | - | $16.20 M(+18.2%) |
| Mar 1995 | - | $13.70 M(-23.5%) |
| Dec 1994 | $17.90 M(+36.6%) | $17.90 M(+8.5%) |
| Sep 1994 | - | $16.50 M(-24.0%) |
| Jun 1994 | - | $21.70 M(+97.3%) |
| Mar 1994 | - | $11.00 M(-16.0%) |
| Dec 1993 | $13.10 M(+184.8%) | $13.10 M(+39.4%) |
| Sep 1993 | - | $9.40 M(+27.0%) |
| Jun 1993 | - | $7.40 M(+19.4%) |
| Mar 1993 | - | $6.20 M(+34.8%) |
| Dec 1992 | $4.60 M(+39.4%) | $4.60 M(-13.2%) |
| Sep 1992 | - | $5.30 M(+26.2%) |
| Jun 1992 | - | $4.20 M(+5.0%) |
| Mar 1992 | - | $4.00 M(+21.2%) |
| Dec 1991 | $3.30 M(+83.3%) | $3.30 M(+57.1%) |
| Sep 1991 | - | $2.10 M(+5.0%) |
| Jun 1991 | - | $2.00 M(+11.1%) |
| Dec 1990 | $1.80 M | $1.80 M |
FAQ
- What is Regeneron Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual current liabilities year-on-year change?
- What is Regeneron Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly current liabilities year-on-year change?
What is Regeneron Pharmaceuticals annual total current liabilities?
The current annual current liabilities of REGN is $3.94 B
What is the all time high annual current liabilities for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual total current liabilities is $3.94 B
What is Regeneron Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, REGN annual total current liabilities has changed by +$520.90 M (+15.22%)
What is Regeneron Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of REGN is $3.94 B
What is the all time high quarterly current liabilities for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly total current liabilities is $3.94 B
What is Regeneron Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, REGN quarterly total current liabilities has changed by +$520.90 M (+15.22%)